Pharm Block 1 drugs

  1. Amphetamine mechanism
    • Indirectly acting adrenergic agonist
    • Competitively inhibits the dopamine transporter (DAT), goes in cell, and interferes with VMAT filling of dopamine
    • Cytoplasmic increase in DA increases, refersing direction of DAT, pushing DA out of cell into cleft
  2. Amphetamine uses
    • ADHD
    • Narcolepsy
  3. Cocaine mechanism
    • Indirectly acting adrenergic agonist
    • Inhibits DA tranpsorter (DAT), increasing synaptic cleft dopamine
    • Inhibits NE transporter (NET) to increase NE
  4. Modafinil
    Weak amphetamine-like effects
  5. Phenelzine mechanism
    • MAO-A inhibitor
    • Metabolizes NE, epi, 5HT, DA, and tyramine, but not amphetamine
  6. Phenelzine adverse effects
    Wine & cheese reaction- HTN
  7. What is the wine and cheese reaction?
    • Severe HTN by interaction of MAO-A inhibitors and cheese-containing foods and adrenergic drugs
    • Cheese has tyramine.
    • Normally, tyramine is a wimpy transmitter but if there's too much (bc it's not getting broken down by MAO), then there's an increase in NE and thus increase in BP.
  8. Reserpine mechanism
    Block DA vesicle formation by blocking VMAT-mediated storage in granule
  9. Selegiline mechanism
    MAO-B inhibitor only present in the brain
  10. Epinephrine mechanism
    • alpha1, beta1, and beta2 agonist
    • alpha1: vasoconstriction, increase in BP
    • beta1: increased HR
    • beta2: vasodilation, decreased diastolic pressure
  11. Epinephrine uses
    • Low/moderate dose: beta2 > alpha1, decreases resistance and decreases diastolic pressure
    • High dose: alpha1 > beta2, increases diastolic pressure
    • Bronchial asthma: beta2 dilates bronchioles (primatene?)
  12. Norepinephrine mechanism
    • alpha1 and beta1 agonist
    • alpha1: increases diastolic pressure, vasoconstriction
    • beta1: increases HR, (+) inotrope = increase pulse pressure
    • Reflex bradycardia: NE has beta1 + vagal reflex thru ACh (ACh > NE)
  13. Norepinephrine use
    Pressor agent used to increase BP in hypotensive state
  14. Dopamine mechanism
    • Low dose: DA-1 receptor (D1)- Increases cAMP in renal blood vessel = vasodilation
    • Medium dose: beta1- inotropic and chronotropic
    • Large dose: alpha1- vasoconstriction
  15. Dopamine use
    Used in renal failure with shock
  16. Fenoldopam mechanism
    D1 agonist
  17. Fenoldopam use
    Hypertensive crisis
  18. Ephedrine mechanism
    • Mixed adrenergic agonist
    • Acts directly on alpha and beta receptors
    • Indirectly increases NE release, and blocks NE reuptake
    • Resistant to MAO
  19. Ephedrine use
    • Bronchial asthma (beta2 bronchodilates)
    • Hypotension after spinal anesthesia
  20. Phenylephrine mechanism
    • alpha1 agonist
    • Constricts arterioles = increases diastolic pressure
    • Reflex bradycardia due to carotid baroreceptors
  21. Phenylephrine use
    • Hypotensive state
    • Nasal decongestant
    • Mydriatic effect (pupil dilation)
  22. Clonidine mechanism
    • alpha2 agonist
    • Inhibits NE release
    • Decreases BP
  23. Clonidine uses
    • HTN
    • ADHD
    • Given with amphetamines to downregulate alpha2 activity
  24. Clonidine adverse effects
    • Sedation
    • Bradycardia
    • Rebound HTN
  25. Apraclonidine + Brimonidine mechanism
    • alpha2 agonist
    • Reduces formation of aqueous humor
  26. Apraclonidine + Brimonidine use
    Add-on choice for glaucoma tx
  27. Methyldopa mechanism
    • alpha2 agonist
    • Shuts down DA and NE synthesis by blocking dopa-decarboxylase
    • Inhibits sympathetics and lowers BP
  28. Methyldopa use
    HTN with PREGNANCY
  29. Dobutamine mechanism
    • beta1 agonist
    • Milder
    • Does not act on DA receptors
    • Increases contraction of heart, but only weakly increases HR
  30. Dobutamine use
    • Acute heart failure
    • Cardiogenic shock
  31. Isoproterenol mechanism
    • Non-selective beta1 and beta2 agonist
    • beta1: Inotropic and chronotropic; tachycardia & sympathetic reflex
    • beta2: dilates arterioles; peripheral resistance decreases; diastolic pressure decreases, causes reflex tachycardia
  32. Isoproterenol use
    • Stimulate AV conduction (beta1)
    • Dilate bronchioles (beta2)
  33. Albuterol mechanism
    Short acting beta2 agonist (SABA)
  34. Albuterol use
    Acute asthma relief
  35. Tertbutaline mechanism
    Short acting beta2 agonist (SABA)
  36. Tertbutaline use
    • Asthma relief
    • Uterine smooth muscle relaxant
  37. Formoterol + Salmeterol mechanism
    Long acting beta2 agonist (LABA)
  38. Formoterol + Salmeterol use
    • PREVENTION of asthma
    • Not for acute bc slower onset of action
    • Must be given with GLUCOCORTICOID bc long-term medication downregulates receptors and steroids increase their transcription
  39. Mirabegron mechanism
    beta3 agonist
  40. Mirabegron use
    Overactive bladder
  41. alpha1 blockage
    • Inhibition of eye radial fiber contraction (mydriasis) -> miosis
    • Inhibition of vessel contraction -> decrease in peripheral resistance, vessel dilation, decreased BP, postural hypotension
    • Nasal vessel dilation and increase in mucus gland secretion -> nasal congestion
    • Inhibition of bladder trigone and sphincter contraction -> urinary outflow
    • Inhibition of ejaculation
  42. alpha2 blockage
    • Inhibition of decrease of NE release -> increase NE release
    • Inhibition of decrease of insulin release -> increase insulin release
    • Inhibition of increasing platelet aggregation -> inhibition of platelet aggregation
  43. Phentolamine mechanism
    non-selective reversible alpha blocker
  44. Phentolamine use
    Pheochromocytoma
  45. Phenoxybenzamine mechanism
    non-selective irreversible alpha blocker
  46. Phenoxybenzamine use
    Pheochromocytoma
  47. Tamsulosin mechanism
    selective reversible alpha1a blocker
  48. Tamsulosin use
    • Benign prostatic hyperplasia (promotion of urinary outflow)
    • Removes inhibitory action of sympathetics
  49. Prasozin + Terazosin mechanism
    selective reversible alpha1 blocker
  50. Prasozin + Terazosin use
    • HTN
    • Benign prostatic hyperplasia
  51. beta1 blockage
    • Inhibits increase in heart function -> decrease heart function
    • Inhibits JG cells from releasing renin -> decrease in renin, decrease in BP
  52. beta2 blockage
    • Inhibition of vessel dilation -> vessel constriction
    • Inhibition of uterus relaxation -> uterus contraction
    • Inhibition of bronchi dilation -> bronchi constriction
  53. beta blocker adverse effects
    • AV block and bradycardia
    • bronchial asthma and COPD
    • Cold extremities from little venous return and blood pooling
    • Hyperlipidemia
    • Sexual dysfunction
  54. A-BEAM
    • cardio-selective beta1 blockers
    • Atenolol
    • Brisprolol
    • Betaxolol
    • Esmolol
    • Acebtolol
    • Metoprolol
  55. A-BEAM use
    • CAD
    • Diabetes
  56. Labetalol + Carvedilol mechanism
    • non-selective beta blocker and alpha1 blocker
    • beta1 = beta2
    • Better vasodilator bc blocks alpha1
  57. Labetalol + Carvedilol uses
    • CHF
    • HTN in pregnancy
  58. Propranolol mechanism
    • non-selective beta blocker
    • beta1 blocker: (-) chronotropic action (decrease HR) and blocks reflex tachycardia; AV conduction is decreased
    • beta2 blocker: (-) inotropic action (decrease pulse pressure)
  59. Propranolol use
    • Hyperthyroidism
    • Glaucoma- reduces aqueous humor production
  60. Propranolol adverse effects
    • Can lead to bronchial asthma by blocking beta2 (causing bronchoconstriction)
    • Caution for people with diabetes
  61. Timolol mechanism
    beta1 and beta2 blocker
  62. Timolol use
    • Glaucoma- reduce formation of aqueous humor and possibly increase outflow
    • But second choice for glaucoma, alternative to PGF2a
  63. Timolol adverse effects
    Can cause severe bronchospasm in asthmatics
  64. Acetylcholine mechanism
    N & M agonist
  65. Acetylcholine use
    ACh-induced nitric oxide mediated vasodilation
  66. Bethanechol mechanism
    • Cholinomimetic
    • M agonist
  67. Bethanechol use
    • Non-obstructive urinary retention
    • Atony of the GI tract and bladder
    • Megacolon
  68. Bethanechol adverse effects
    • Resistant to hydrolysis by AChE
    • Can cause cholinergic effects like sweating, salivation, flushing
  69. Pilocarpine mechanism
    • Cholinomimetic
    • N & M agonist
    • DOES cross BBB, so used in CNS
  70. Pilocarpine use
    • Applied ot cornea for spasm of accomodation
    • Choice for all glaucoma
    • Sjogren's syndrome
  71. Carbachol mechanism
    • Cholinomimetic
    • N & M agonist
  72. Carbachol use
    Glaucoma
  73. Carbachol adverse effects
    • Resistant to hydrolysis by AChE
    • Can cause cholinergic effects like sweating, salivation, flushing
  74. Methacholine mechanism
    • Cholinomimetic
    • M agonist
  75. Methacholine use
    Bronchial hyperactivity
  76. Methacholine adverse effects
    Susceptible to cholinesterase
  77. Edrophonium mechanism
    • Reversible anticholinesterase
    • Inhibits acetylcholinesterase: prolonged duration of ACh
    • Short acting 5-15 mins
  78. Edrophonium use
    Tensilon TEST for myasthenia gravis (not treatment)
  79. Neostigmine mechanism
    • Reversible anticholinesterase
    • Does NOT cross BBB bc charged, so no CNS action
  80. Neostigmine use
    • TREATMENT of myasthenia gravis
    • Directly stimulates receptor & also indirectly inhibits AChE- reverses NM blockade
  81. Physostigmine mechanism
    • Reversible anticholinesterase
    • DOES cross BBB, so CNS action
  82. Physostigmine use
    • Glaucoma
    • Antidote in atropine poisoning
    • Bladder atony
  83. Pyridostigmine mechanism
    • Reversible anticholinesterase
    • Does NOT cross BBB, so NO CNS action
  84. Pyridostigmine use
    • Myastenia gravis
    • Prevention of nerve gas poison (soman)
  85. Donepezil mechanism
    • Reversible anticholinesterase
    • Does NOT cross BBB, so NO CNS action
  86. Donepezil use
    Alzheimer's and dementia
  87. Demecarium mechanism
    Reversible anticholinesterase
  88. Demecarium use
    Open and closed angle glaucoma
  89. Echothiophate mechanism
    • Irreversible anticholinesterase
    • Organophosphate
    • Binds covalently and permanently inactivates the enzyme
  90. Organophosphate poisoning/aging
    Aging occurs when ethyl group is released, so bond between drug and rest of enzyme is strengthened and can't be broken
  91. Echothiophate use
    • Miosis (induces mydriasis)- so will dilate the pupil
    • Increases outflow of aqueous humor which decreases IOP
    • Chronic open angle glaucoma
    • Subacute or chonic angle closure glaucoma after iridectomy
    • Or when surgery is contraindicated
  92. Parathion, malathion, diazinon (TIK-20) mechanisms
    • Irreversible anticholinesterase
    • Organophosphates
  93. Pralidoxime (PAM) mechanism
    • Cholinesterase reactivator
    • Attaches to anionic site of AChE in presence of organophosphates and sets enzyme freeeee
    • Used with ATROPINE
  94. Pralidoxime (PAM) use
    • Antidote for organophosphate poisoning (used with ATROPINE)
    • Treat nerve gas poison (sarin, soman) which are irreversible anticholinesterases
  95. Pralidoxime (PAM) adverse effects
    Not recommended in oversdoses of stigmines
  96. Atropine mechanism
    M antagonist
  97. Atropine use
    • Control bradycardia: increases HR and BP
    • Induce mydriasis
    • Cycloplegia (paralysis of accomodation)
  98. Atropine adverse effects
    • Overdose: hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter
    • Do not use in glaucoma or urinary retention
  99. Scopolamine mechanism
    M antagonist
  100. Scopolamine use
    Motion sickness
  101. Ipratropium mechanism
    • M3 antagonist (anticholinergic)
    • Slower onset of action, sometimes given with LABA in baseline asthma
  102. Ipratropium use
    • COPD
    • Asthma
    • Alternative for people who cannot tolerate beta2 agonists
    • Sometimes given with LABA in baseline asthma
  103. Glycopyrrolate mechanism
    • M antagonist
    • Works in glands/heart
  104. Glycopyrrolate use
    • Preanesthetic med
    • Control bradycardia
  105. Cyclopentolate mechanism
    • M antagonist
    • Works on eyes
  106. Cyclopentolate use
    Fundoscopic exam (dilates eyes)
  107. Darifenacin + Tolterodine mechanism
    • M antagonist
    • Works in urinary bladder
  108. Darifenacin + Tolterodine use
    Overactive bladder
  109. Trihexyphenidyl + Benzotropine mechanism
    • M antagonist
    • Works in CNS
  110. Trihexyphenidyl + Benzotropine use
    Parkinson's disease
  111. Succinylcholine mechanism
    • Depolarizing NMJ blocker
    • Excites so strongly -> desensitization
    • Downregulates receptor so it can no longer release ACh
  112. Succinylcholine use
    Paralytic
  113. Tubocurarine mechanism
    • Non-depolarizing NMJ blocker
    • Blocks N1 receptors at the NMJ
  114. Tubocurarine use
    Paralytic
  115. Hexamethonium mechanism
    • GANGLIONIC N2 blocker- blocks para and sym ganglia
    • Non-depolarizing
  116. Hexamethonium use
    • BLOCKS REFLEX bradycardia that occurs with phenylephrine
    • Used to study direct effect of drug and not reflexes
  117. Botulinum toxin mechanism
    • Non-depolarizing NMJ blocker
    • Blocks NT release by degrading SNAP-25, required for vesicle fusion and ACh release
    • Blocking ACh produces flaccid paralysis of skeletal muscle and diminished activity of cholinergic synapses
  118. Botulinum toxin use
    • Chronic migraine prophylaxis
    • Blepharospasm
    • Cervical dystonia
    • Hyperhydrosis- stop sweating
  119. Imipramine mechanism
    • Blocks the NET and prevents NE reuptake
    • Also has anticholinergic activity
  120. Imipramine use
    Tricyclic antidepressant
  121. Hemicholinium mechanism
    Inhibits choline carrier so ACh cannot be synthesized
  122. Latanoprost mechanism
    • PGF2a analog: Increases outflow of aqueous humor thru accessory uveoscleral outflow path, reduces IOP
    • Eye drops
  123. Latanoprost use
    First choice for glaucoma by reducing IOP thru aqueous humor drainage
  124. Latanoprost adverse effects
    Increase iris pigmentation
  125. Acetazolamide + Dorzolamide mechanism
    • Carbonic anhydrase inhibitor
    • Decreases aqueous humor PRODUCTION
  126. Acetazolamide + Dorzolamide use
    Glaucoma
  127. Triotropium mechanism
    • M3 antagonist (antichoinergic)
    • Slower onset of action
  128. Triotropium use
    • Asthma
    • COPD
    • Bronchodilator
    • Alternative for people who cannot tolerate beta2 agonists
  129. Beclomethasone, Budesonide, Flunisolide, Fluticasone, Triamcinolone, Prednisone (-one, -ide) mechanisms
    • Glucocorticoid
    • Bind to intracellular glucocorticoid receptors and modulate gene expression
    • Increases levels of lipoprotein 1 which inhibits PLA2 = anti-inflammation
  130. Beclomethasone, Budesonide, Flunisolide, Fluticasone, Triamcinolone, Prednisone (-one, -ide) uses
    Chronic asthma
  131. Beclomethasone, Budesonide, Flunisolide, Fluticasone, Triamcinolone, Prednisone (-one, -ide) adverse effects
    • Adrenal atrophy
    • Peptic ulcer
    • Oral candidiasis
  132. Theophylline + Roflumilast mechanism
    • PDE inhibitor (PDE4 specifically for roflumilast)
    • Inhibits breakdown of cAMP
    • Increased cAMP maintains bronchodilation and blocks adenosine receptors
  133. Theophylline + Roflumilast use
    • Relieves asthma
    • (and COPD?)
  134. Theophylline + Roflumilast adverse effects
    • Cardiac arrhythmias
    • Caffeine-like adverse effects- N/V, headache, insomnia
    • Persistent vomiting
    • Intractable seizures which can be fatal
  135. Zileuton mechanism
    Lipoxygenase inhibitor: Prevents leukotriene synthesis
  136. Zileuton use
    • Persistent asthma, allergic reactions, allergic asthma uncontrolled on low dose ihaled corticosteroids
    • Causes bronchodilation
  137. Zileuton adverse effects
    • Minimal
    • Hepatotoxicity
  138. Zafirlucast mechanism
    • Leukotriene D4 receptor antagonist
    • Blocks leukotriene receptors
  139. Zafirlucast use
    • Persistent asthma, allergic reactions, allergic asthma uncontrolled on low dose ihaled corticosteroids
    • Causes bronchodilation
  140. Omalizumab mechanism
    Humanized anti-IgE monoconal Ab
  141. Omalizumab use
    3rd line drug for chronic severe asthma that is not controlled by anything else (like high dose inhaled corticosteroid & LABA)
  142. Omalizumab adverse effects
    • Expensive
    • Anaphylaxis
    • SQ q2-4 weeks
  143. Montelukast mechanism
    • Leukotriene D4 receptor antagonist
    • Blocks leukotriene receptors
  144. Montelukast use
    • Persistent asthma, allergic reactions, allergic asthma uncontrolled on low dose ihaled corticosteroids
    • Causes bronchodilation
  145. Nedocromil + Sodium cromoglycate mechanism
    Mast cell stabilizers (cromones)
  146. Nedocromil + Sodium cromoglycate use
    • Only send prophylactially for alleric rhinitis
    • Do not relieve bronchospasm
  147. Omeprazole mechanism
    • PPI
    • Decreases acid secretion by irreversibly binding to H+/K+ ATPase
  148. Omeprazole use
    • Peptic ulcer disease & GERD
    • Drug of choice for ZOLLINGER-ELLISON SYNDROME
    • Treat NSAID ulcers
  149. Omeprazole adverse effects
    • Cyp450 inhibitor
    • Do not use with clopidogrel or warfarin (blood thinners)
  150. Pantoprazole mechanism
    • PPI
    • Decreases acid secretion by irreversibly binding to H+/K+ ATPase
  151. Pantoprazole use
    • Peptic ulcer diseaes & GERD
    • Drug of choice for ZOLLINGER-ELLISON SYNDROME
    • Treat NSAID ulcers
    • NOT a Cyp450 inhibitor so OKAY to use with clopidogrel and warfarin (blood thinners)
  152. Cimetidine mechanism
    H2 receptor antagonist
  153. Cimetidine use
    • GERD
    • Ulcers
    • Zollinger-Ellison syndrome
  154. Cimetidine adverse effects
    • GYNECOMASTIA in men
    • INFERTILITY
    • GALACTORRHEA in women
  155. Ranitidine mechanism
    H2 receptor antagonist
  156. Ranitidine use
    • GERD
    • Ulcers
    • SAFE IN PREGNANCY
  157. Famotidine + Nizantidine mechanism
    H2 receptor antagonist
  158. Famotidine + Nizantidine use
    • GERD
    • Ulcers
  159. Aluminum hydroxide mechanism
    Antacids
  160. Aluminum hydroxide adverse effects
    Aluminum causes constipation
  161. Magnesium hydroxide mechanism
    • Antacid
    • Osmotic laxative: water retention by osmosis, increased CCK
  162. Magnesium hydroxide use
    Laxative
  163. Magnesium hydroxide adverse effect
    • Diarrhea
    • Avoid in renal failure
  164. Why are aluminum hydroxide and magnesium hydroxide taken together as an antacid?
    They cancel out their adverse effects (constipation and diarrhea respectively)
  165. Calcium carbonate use
    Antacid
  166. Calcium carbonate adverse effects
    • Milk alkali syndrome: hypercalcemia, alkalosis
    • Belching
  167. Sodium bicarbonate use
    Antacid
  168. Misoprostol mechanism
    • PGE1 analog: cytoprotective, reduces acid production
    • Enhances mucous secretion and blood flow
  169. Misoprostol use
    • PREVENTION & treatment of ulcers in patients on NSAIDs
    • Induces ABORTION
  170. Misoprostol adverse effects
    Contraindicated in pregnancy bc induces abortion
  171. Sucralfate mechanism
    • Forms physcial BARRIER to prevent further damage by stimulating prostaglandins
    • Needs an acidic medium- DO NOT take with PPI
  172. Sucralfate use
    • GERD
    • SAFE IN PREGNANCY- first line
  173. Sucralfate adverse effects
    Constipation
  174. Bismuth subsalicylate mechanism
    Bismuth salt binds pepsin & stimulates prostaglandins & mucous secretions
  175. Bismuth subsalicylate use
    • Dyspepsia
    • Traveler's diarrhea
    • H. pylori
  176. Bismuth subsalicylate adverse effects
    Black tongue
  177. Colloidal bismuth subcitrate
    Everything is the same as bismuth subsailcylate
  178. Diphenhydramine mechanism
    H1 receptor antagonist
  179. Diphenhydramine use
    • Motion sickness
    • Allergies
  180. Dimenhydrinate mechanism
    H1 blocker
  181. Dimenhydrinate use
    Motion sickness
  182. Promethazine mechanism
    H1 blocker
  183. Promethazine use
    Motion sickness
  184. Metoclopromide mechanism
    • Dopamine D2 antagonist
    • Blocks suppression of the release of ACh from the myenteric plexus (so increases ACh release)
  185. Metoclopromide use
    • Constipation
    • GERD
    • Gastroparesis in diabetes
  186. Metoclopromide adverse effects
    • Acute dystonias
    • Parkinsonism
    • Hyperprolactinoma
  187. Ondansetron mechanism
    • 5-HT3 antagonist
    • Vaginal inhibition
  188. Ondansetron use
    N/V post surgery or chemo
  189. Ondansetron adverse effects
    • Constipation
    • QT interval prolongation
    • Serotonin syndrome with SSRI
  190. Arepitant + Fosaprepitant + Rolapitant mechanism
    Substance P antagonist
  191. Arepitant + Fosaprepitant + Rolapitant use
    • Delayed nausea
    • Used in combo with corticosteroids & serotonin 5-HT3 antagonists for the prevention of acute & also delayed N/V with highly emetogenic chemo regimens
  192. Arepitant + Fosaprepitant + Rolapitant adverse effects
    Avoid in those with QT prolongation
  193. Pyridoxine (B6) + doxylamine use
    Hyperemesis gravidarum
  194. Dexamethasone mechanism
    Corticosteroid
  195. Lorazepam mechanism
    Benzodiazepine
  196. Lorazepam use
    Anticipatory nausea
  197. Dronobinol (THC) mechanism
    Cannabinoid agonist
  198. Dronobinol (THC) use
    • Stimulates appetite
    • Used for anorexia in HIV/AIDS
    • Prevention of chemo induced n/v (CIN/V)
  199. Dronobinol adverse effects
    • Paranoid reactions
    • Abnormal thinking
  200. Nabilone mechanism
    THC analog
  201. Nabilone use
    Prevention of refractory chemo induced n/v (CIN/V)
  202. Nabilone adverse effects
    • Paranoid reactions
    • Abnormal thinking
  203. Methylcellulose + Psyllium mechanism
    • Bulk forming laxatives
    • SAFE FOR PREGNANCY
  204. Methylcellulose + Psyllium use
    • Laxative
    • SAFE FOR PREGNANCY
  205. Methylcellulose + Psyllium adverse effects
    Bloating
  206. Bisacodyl mechanism
    • Stimulant laxative- act by inducing low grade inflammation
    • Activates cAMP & cGMP pathways
    • Inhibition of Na+/K+ ATPase
  207. Bisacodyl use
    Short-term use in consultation
  208. Bisacodyl adverse effects
    Avoid chronic use in pregnancy
  209. Senna
    Same as bisacodyl
  210. Senna adverse effect
    • Avoid chronic use in pregnancy
    • Melanosis coli
  211. Docusate sodium mechanism
    • Stool softener, anionic surfactants reduce surface tension of the stool to allow mixing of aqueous and fatty substances
    • SAFE FOR PREGNANCY
  212. Docusate sodium use
    • Laxative
    • SAFE FOR PREGNANCY
  213. Docusate sodium adverse effects
    Lipid pneumonitis
  214. PEG mechanism
    Osmotic laxative: water retention by osmosis, increased CCK
  215. PEG use
    • Laxative
    • Used before colonoscopy
  216. PEG adverse effects
    Avoid in renal failure
  217. Lactulose mechanism
    • Osmotic laxative
    • Disaccharide that resists intestinal metabolism of disaccharides, so they are hydrolyzed to short-chain fatty acids
    • Stimulates propulsive motility by osmotic activity
    • Acidifies the colonic contents which leads to the formation of NH4+ (non-absorbable) from NH3, and increases ammonium excretion
  218. Laculose use
    • Hepatic encephalopathy- forms NH4+ so that it can't cross BBB
    • Constipation
  219. Loperamide mechanism
    Opioid agonist
  220. Loperamide use
    Acute non-severe diarrhea (in elderly)
  221. Lubiprostone mechanism
    Chloride channel activator- increases cAMP to increase Cl- selection
  222. Lubiprostone use
    • Chronic constipation
    • IBS with constipation (IBS-C)
    • Opioid induced constipation
  223. Lubiprostone adverse effects
    Contraindicated in pregnancy
  224. Linaclotide mechanism
    Chloride channel activator- agonist of gruanylyl cyclase that leads to activation of CFTR with stimulation of chloride rich secretion
  225. Linaclotide use
    • Constipation
    • IBS-C
  226. Methylnaltrexone + Naloxegol mechanism
    • Peripherally acting opioid receptor antagonist
    • Blocks opioid receptors in the GI tract peripherally
    • Does NOT cross BBB
    • No limiting of analgesic action centrally
  227. Methylnaltrexone + Naloxegol use
    Opioid induced constipation
  228. Mesalamine mechanism
    Azo-linked (5-ASA, 5-aminosalicylates)
  229. Mesalamine use
    #1 drug for IBS- preferred over sulfasalazine
  230. Sulfasalazine mechanism
    • Azo-linked (5-ASA) to sulfapyridine
    • DMARD
  231. Sulfasalazine use
    IBS
  232. Sulfasalazine adverse effects
    Causes bone marrow suppression & infertility so no longer used....
  233. Ursodeoxycholic acid (UDCA) mechanism
    Decreases hepatic cholesterol secretion and reduces the cholesterol content of bile
  234. Ursodeoxycholic acid (UDCA) use
    • Oral bile acid dissolution therapy for gallstones
    • But high risk of recurrence
  235. Cetirizine mechanism
    • H1 receptor antagonist
    • 2nd gen- lacks sedative properties
  236. Sodium chormolyn mechanism
    Prevents mast cells from releasing histamine
  237. Cyproheptadine mechanism
    • H1 receptor antagonist
    • 1st gen- some drowsiness
    • 5-HT2a blocker
    • No associated arrhythmia
  238. Cyproheptadine use
    • Motion sickness
    • Allergy
    • Sedative
    • POSTGASTRECTOMY DUMPING SYNDROME
  239. Fexofenadine mechanism
    • H1 receptor antagonist
    • 2nd gen- lacks sedative properties
  240. Loratidine mechanism
    • H1 receptor antagonist
    • 2nd gen- lacks sedative properties
  241. Promethazine mechanism
    • H1 receptor antagonist
    • 1st gen- some drowsiness
  242. Promethazine use
    Motion sickness
  243. Chlorpheniramine, Pyrilamine, Cyclizine mechanisms
    H2 receptor antagonist
  244. Terfenadine + Astemizole mechanism
    • H1 receptor antagonist
    • 2nd gen- lacks sedative properties
  245. Fluoxetine mechanism
    SSRI inhibits 5-HT reputable
  246. Sumatriptan mechanism
    5-HT1B/1D agonist
  247. Sumatriptan use
    Migraines
  248. Sumatriptan adverse effects
    • Coronary vasospasms with resulting chest pain
    • Contraindicated in pts with angina
  249. Rizatriptan mechanism
    5-HT1B/1D agonist
  250. Rizatriptan use
    • Migraines
    • Most rapid onset
    • Co-administration with propanolol increases levels by 70%
  251. Rizatriptan adverse effects
    • Coronary vasospasms with resulting chest pain
    • Contraindicated in pts with angina
  252. Zomitriptan + Naratriptan mechanism
    5-HT1B/1D agonist
  253. Zomitriptan + Naratriptan use
    Migraines
  254. Zomitriptan + Naratriptan adverse effects
    • Coronary vasospasms with resulting chest pain
    • Contraindicated in pts with angina
  255. Methysergide mechanism
    5-HT2 (2A, 2B, 2C) antagonist
  256. Methysergide use
    • Migraine PROPHYLAXIS
    • Protective effect takes 1-2 days to develop
  257. Lorcaserin mechanism
    5-HT2C agonist
  258. Lorcaserin use
    Appetite suppressant
  259. Acetylsalicylic acid (aspirin) mechanism
    • Irreversible non-selective COX1 & COX2 inhibitor
    • Binds by acetylation
    • Uncouples OXIDATIVE PHOSPHORYLATION- inhibits ATP dependent reaction
  260. Acetylsalicylic acid (aspirin) use
    • Low doses (50-360mg): inhibits TXA2 - antiplatelet
    • Medium doses: inhibits PGE2 - analgesic & antipyretic
    • High doses: anti-inflammatory when given regularly for a long time (RHEUMATOID ARTHRITIS)
  261. Acetylsalicylic acid (aspirin) adverse effects
    • Mild intoxication- respiratory alkalosis
    • Severe OD- metabolic acidosis
    • REYE'S SYNDROME: Children under 12 presenting with swollen brain and liver leading to death
    • Gastric ulcers
    • Contraindicated in gout- inhibits excretion of uric acid
  262. Ibuprofen mechanism
    • Reversible non-selective COX1 & COX2 inhibitor
    • Same potency as aspirin but better tolerated
  263. Ibuprofen uses
    • Analgesic & antipyretic
    • Anti-inflammatory- rheumatoid arthritis, osteoarthritis
  264. Ketoprofen mechanism
    Inhibits COX and may also inhibit lipoxygenase- will decrease PG, TX, & LTs
  265. Ketoprofen use
    May be desirable for asthmatics or inflammation & allergic response bc LTs cause bronchospasm and constriction
  266. Indomethacin mechanism
    Non-selective COX1 & COX2 inhibitor
  267. Indomethacin use
    • CLOSES PDA
    • Gouty arthritis (#1 tx for acute gout)
  268. Indomethacin adverse effects
    More potent than aspirin but inferior at doses tolerated by RA pts
  269. Sulindac mechanism
    • Inactive pro-drug closely related to indomethacin
    • Must be metabolized by hepatic microsomal enzymes to active form
    • Long duration of action; half life ~8 hrs
  270. Sulindac use
    Like indomethacin but adverse effects are less severe than NSAIDs
  271. Phenylbutazone mechanism
    Non-selective COX1/COX2 inhbitor
  272. Phenylbutazone use
    • Potent anti-inflammatory but sefulness is limited by toxicity
    • Chiefly short term therapy
  273. Celecoxib mechanism
    Irreversible selective COX2 inhibitor
  274. Celecoxib use
    • Chronic arthritis
    • NO GI irritation/ulceration
    • Antipyretic & analgesic
  275. Celecoxib adverse effects
    • Controversy of increased risk of clotting & MI
    • Increases level of lithium and warfarin
  276. Acetaminophen mechanism
    • COX3? inhibitor
    • Weak inhibition of COX1 & COX2
  277. Acetaminophen use
    Antipyretic & analgesic
  278. Acetaminophen adverse effects
    • Small theraputic index
    • Uses up liver GLUTATHIONE which leads to liver damage- fatal hepatotoxicity
  279. What is the antidote for hepatotoxicity from acetaminophen OD?
    N-acetylcysteine- brings GLUTATHIONE back
  280. Alprostadil mechanism
    • PGE1 analog
    • IV infusion
    • Penile suppository
  281. Alprostadil use
    • MAINTAINS PDA
    • Erectile dysfunction
    • Vasodilator
  282. Dinoprostone mechanism
    • PGE2 analog
    • Vaginal pessary
  283. Dinoprostone use
    • Abortifacient & induction of labor
    • Postpartum hemorrhage
    • Promotes uterine contraction
  284. Dinoprostone adverse effects
    Abortifacients
  285. Carboprost mechanism
    PGF2a analog
  286. Carboprost use
    Abortifacient
  287. Epoprostenol mechanism
    • PGI2 analog
    • IV infusion
  288. Epoprostenol use
    • Pulmonary HTN
    • Inhibits platelet aggregation, lowers BP
  289. Colchicine mechanism
    • Inhibits microtubule polymerization in PMNs
    • Inhibits cell migration, adherance, degranulation
    • Inhibits IL-8, ICAM, E-selectin, L-selectin, IL-1
    • Anti-neutrophils
    • Decreases lactic acid production by leukocytes- decrease in uric acid deposition
    • Decrease phagocytosis- decrease in inflammatory response
  290. Colchicine use
    • Abortive therapy in ACUTE GOUT- first 12 hrs
    • Used as combination therapy with ALLOPURINOL & PROBENECID
    • 2nd line in acute gout (indomethacin is 1st)
  291. Colchicine adverse effects
    • CANNOT be used in pregnancy- may cross placenta & is found in breast milk
    • Interacts with- cimetidine, terfenadine, EES, ketoconazole, diltazepam, nifedipine cyclosporin, statins
    • Toxicity:<24 hrs = AP, N/V, diarrhea, dehydration skin irritation; 24-72 hrs = organ failure, anemia, lots of bad stuff
  292. Prednisone mechanism
    • Block action of PLA2
    • Glucorticoid
    • Ideally should be given at most every 3 months
  293. Prednisone use
    • Acute gout- when NSAID+colchicine combo is contraindicated
    • Effective short term pain relief, short term increase of joint strength
    • Local anti-inflammatory
  294. Triamcinolone mechanism
    Intra-articular glucocorticoids
  295. Triamcinolone use
    For gout pts unable to take oral meds, with only 1 or 2 inflamed joints, and infection is ruled out
  296. Triamcinolone disadvantages
    • Mild flare of synovitis
    • Low risk of infection
    • Short term option
    • Risk of cartilage damage with repeated use
  297. Probenecid, Sulfinpyrazone, Benzobromarone mechansims
    • Bind to proximal convoluted tubule (PCT) to increase renal excretion of uric acid
    • Uricosurics- promote excretion
  298. Probenecid, Sulfinpyrazone, Benzobromarone use
    • Gout with NORMAL uric acid secretion
    • For PROPHYLAXIS in pts who have had recurrent attacks of acute gouty arthritis
    • Tx of choice for CHRONIC gout
  299. Probenecid, Sulfinpyrazone, Benzobromarone adverse effects
    • Initiation of therapy may induce acute attack, caused by mobilization of urate from other sites to inflamed joints
    • Prophylactic use of NSAIDs
  300. Allopurinol mechanism
    • Xanthine oxidase inhibitor
    • Results in decrease in synthesis of uric acid
  301. Allopurinol use
    • Chronic gout with EXCESS uric acid excretion, kidney failure, & stones
    • NOT in acute gout
  302. Allopurinol adverse effects
    • Inhibits azathioprine metabolism
    • Dose of azathioprine must be reduced to 1/4th of usual when pt is also taking allopurinol
    • Can lead to severe & fatal rash, discontinue if develops
  303. Febuxostat mechanism
    Xanthine oxidase inhibitor
  304. Fuboxostat use
    Chronic gout in people who cannot use allopurinol
  305. Methotrexate mechanism
    • Inhibits folate reductase- inhibits DNA synthesis
    • Increases adenosine- modulates immune response
    • Diseaes modifying anti-rheumatic drug (DMARD)
  306. Methotrexate use
    • DMARD of choice in rheumatoid arthritis
    • Used when pts have not responded to NSAIDs
  307. Methotrexate adverse effects
    • Can lead to hepatotoxicity
    • Give folic acid
  308. Leflunomide mechanism
    • Inhibits dihydrooratate dehydrogenase- decrease activated T cells
    • DMARD
  309. Leflunomide adverse effects
    • Rash, alopecia
    • Diarrhea
    • Bone marrow toxicity
    • Hepatotoxicity
  310. Azathioprine mechanism
    • Immunosuppressant
    • Corticosteroid sparing
    • DMARD
  311. Hydroxychloroquine mechanism
    • Stabilizes lysosomes & decreases chemotaxis
    • DMARD
  312. Hydroxychloroquine use
    Mild rheumatoid arthritis with methotrexate
  313. Hydroxychloroquine adverse effect
    Can cause hemolysis in people with G6PD
  314. Etanercept, Infliximab, Adalimbumab mechanism
    Anti-TNFa agents
  315. Etanercept, Infliximab, Adalimbumab use
    Rheumatoid arthritis- 2nd choice & given with methotrexate
  316. Etanercept, Infliximab, Adalimbumab adverse effects
    • TB
    • Injection site reaction
  317. Anakinra mechanism
    IL-1 receptor antagonist
  318. Anakinra use
    RA
Author
Mursizzle
ID
356363
Card Set
Pharm Block 1 drugs
Description
AUC Medical Pharmacology block 1 drugs
Updated